Satoko Miyamoto, DO
Psychiatry · Oakland, CANPI 1588839146
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,393 and has fallen 82.9% since, to $238 in 2025.
Across 136 payments — averaging $14.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$324
- Sunovion Pharmaceuticals Inc.$262
- Otsuka America Pharmaceutical, Inc.$260
- AbbVie$259
- Takeda Pharmaceuticals U.S.A., Inc.$169
- Shire North American Group Inc$160
- plus $583 from 8 others
What the payments were for
- Food & beverage$2,013100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 15 | $324 |
| Sunovion Pharmaceuticals Inc. | 22 | $262 |
| Otsuka America Pharmaceutical, Inc. | 14 | $260 |
| AbbVie | 38 | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $169 |
| Shire North American Group Inc | 10 | $160 |
| Alkermes, Inc. | 5 | $120 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Johnson & Johnson | 3 | $87 |
| E.r. Squibb & Sons, L.L.C. | 3 | $80 |
| Neurocrine Biosciences, Inc. | 2 | $51 |
| Alfasigma USA, Inc. | 3 | $51 |
| Ironshore Pharmaceuticals Inc. | 2 | $47 |
| Bausch Health US, LLC | 2 | $36 |
How this compares
$2,017 in reported general payments places this provider in the 80th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Escitalopram Oxalate | 17 | $962 |
| Aripiprazole | 37 | $935 |
| Bupropion XlBupropion Hcl | 22 | $613 |
| Duloxetine Hcl | 22 | $459 |
| Quetiapine Fumarate | 24 | $425 |
| Olanzapine | 20 | $332 |
| Buspirone Hcl | 15 | $308 |
| Sertraline Hcl | 25 | $292 |
| Mirtazapine | 13 | $271 |
| Trazodone Hcl | 23 | $178 |
| Benztropine Mesylate | 16 | $139 |
| Lamotrigine | 12 | $136 |
| Fluoxetine Hcl | 25 | $108 |
| Gabapentin | 17 | $85 |
| Lithium Carbonate ErLithium Carbonate | 11 | $79 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Oakland
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.